Compare LBRDK & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRDK | CRL |
|---|---|---|
| Founded | 2014 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 8.0B |
| IPO Year | N/A | 2000 |
| Metric | LBRDK | CRL |
|---|---|---|
| Price | $47.74 | $190.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $190.15 |
| AVG Volume (30 Days) | ★ 1.2M | 919.6K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.38 | N/A |
| EPS | ★ 5.51 | N/A |
| Revenue | $1,016,000,000.00 | ★ $4,023,704,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.46 | $1.66 |
| P/E Ratio | $8.52 | ★ N/A |
| Revenue Growth | ★ 306.40 | N/A |
| 52 Week Low | $44.63 | $91.86 |
| 52 Week High | $104.00 | $202.72 |
| Indicator | LBRDK | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 66.37 |
| Support Level | $44.88 | $176.37 |
| Resistance Level | $48.06 | $186.72 |
| Average True Range (ATR) | 1.34 | 5.79 |
| MACD | 0.64 | 1.97 |
| Stochastic Oscillator | 88.63 | 92.37 |
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.